Journal of Pharmaceutical Research and health Care Impact Factor & Information

Journal description

Journal of Pharmaceutical Research and Health Care (JPRHC) is an open access journal publishing original peer-reviewed research articles and circulated electronically via the World Wide Web. JPRHC Published four times per year and aims to provide a platform to the young researchers of pharmaceutical sciences. Subscription to JPRHC is free of charge and Published regularly between 2009 and 2011, when it was discontinued. It was replaced by the Asian Journal of Pharmaceutical Research and Health Care (AJPRHC) ISSN (printed): 2250-1444. ISSN (electronic): 2250-1460.

Current impact factor: 0.00

Impact Factor Rankings

Additional details

5-year impact 0.00
Cited half-life 0.00
Immediacy index 0.00
Eigenfactor 0.00
Article influence 0.00
Website Pharmacy, Pharmaceutical Sciences, Pharmacology, Phjarmaceutics
ISSN 0975-3648
Material type Document
Document type Journal

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: In order to clarify the cost-effectiveness of various ophthalmic solutions used in glaucoma treatment, we compared the daily cost of intraocular pressure (IOP) reduction of 1 mmHg in glaucoma patients. Methods: The daily costs of ophthalmic solutions were calculated by the total number of drops per bottle and the price of the drug. Data pertaining to the change in IOP before vs. after treatment was obtained from the literature. The IOP reduction achieved by each ophthalmic solution was normalized to the reduction achieved by 0.5% timolol maleate. We applied these values to a model patient with baseline IOP of 24 mmHg who showed a 20% reduction (4.8 mmHg) after treatment with 0.5% timolol maleate. Results: The daily cost of IOP reduction of 1 mmHg ranged from 6.7 to 17.0 yen (mean, 11.1 yen), which represents a maximum difference of 2.5-fold. Conclusions: The daily cost of reducing IOP by 1 mmHg differed greatly among ophthalmic solutions. This approach to evaluating the pharmacoeconomics of glaucoma treatment should become part of routine patient management.
    Journal of Pharmaceutical Research and health Care 09/2014; 40(12):500-506.
  • Journal of Pharmaceutical Research and health Care 01/2014; 1(4):142-157.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims: The aim of this study was to explore the practicability of preparation of solid lipid nanoparticles of Glyceryl monostearate containing Dibenzoyl peroxide, Erythromycin base, and Triamcinolone acetonide as model drugs. The physicochemical properties of the prepared formulae like particle size, drug entrapment efficiency, drug loading capacity, yield content and in-vitro drug release behavior were also measured. Methodology: Solid lipid nanoparticles loaded with three model lipophilic drugs were prepared by high shear hot homogenization method. The model drugs used are Dibenzoyl peroxide, Erythromycin base, and Triamcinolone acetonide. Glyceryl monostearate was used as lipid core; Tween 20 and Tween 80 were employed as surfactants and lecithin as co-surfactant. Many formulation parameters were controlled to obtain high quality nanoparticles. The prepared solid lipid nanoparticles were evaluated by different standard physical and imaging methods. The efficiency of drug release form prepared formulae was studied using in vitro technique with utilize of dialysis bag technique. The stability of prepared formulae was studied by thermal procedures and infrared spectroscopy. Results: The mean particle diameter measured by laser diffraction technique was (194.6±5.03 to 406.6±15.2 nm) for Dibenzoyl peroxide loaded solid lipid nanoparticles, (220±6.2 to 328.34±2.5) nm for Erythromycin loaded solid lipid nanoparticles and (227.3±2.5 to 480.6±24) nm for Triamcinolone acetonide loaded solid lipid nanoparticles. The entrapment efficiency and drug loading capacity, determined with ultraviolet spectroscopy, were 80.5±9.45% and 0.805±0.093%, for Dibenzoyl peroxide, 96±11.5 and 0.96±0.012 for Triamcinolone acetonide and 94.6±14.9 and 0.946±0.012 for Erythromycin base respectively. It was found that model drugs showed significant faster release patterns when compared with commercially available formulations and pure drugs (p˂0.05). Thermal analysis of prepared solid lipid nanoparticles gave indication of solubilization of drugs within lipid matrix. Fourier Transformation Infrared Spectroscopy (FTIR) showed the absence of new bands for loaded solid lipid nanoparticles indicating no interaction between drugs and lipid matrix and being only dissolved in it. Electron microscope of scanning and transmission techniques indicated sphere form of prepared solid lipid nanoparticles with smooth surface with size below 100 nm. Conclusions: Solid lipid nanoparticles with small particle size have high encapsulation efficiency, and relatively high loading capacity for Dibenzoyl peroxide, Erythromycin base, and Triamcinolone acetonide as model drugs can be obtained by this method.
    Journal of Pharmaceutical Research and health Care 03/2013; 3(3):326. DOI:10.9734/BJPR/2013/2770
  • Journal of Pharmaceutical Research and health Care 01/2010; 2:163.
  • Journal of Pharmaceutical Research and health Care 01/2010; 2(1-4):135-145.